HCW Biologics Inc. (HCWB) - 10-Q Summary for Period Ended September 30, 2025
Business Context and Reporting Period
This is an unaudited quarterly report (Form 10-Q) for HCW Biologics Inc., a clinical-stage biopharmaceutical company focused on immunotherapies for age-related diseases. The reporting period covers the three and nine months ended September 30, 2025. The Company is currently in a pre-revenue stage regarding its own commercial products, relying on licensing agreements and equity financing. A 1-for-40 reverse stock split was effective on April 11, 2025, and all historical data has been recast.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 | Balance Sheet (Sept 30, 2025) |
|---|---|---|---|
| Revenues | $15,606 | $27,222 | N/A |
| Net Loss | $(4,554,336) | $(8,678,941) | N/A |
| Net Loss Attributable to Common Stockholders | $(4,554,336) | $(18,832,740) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $1,096,909 |
| Total Assets | N/A | N/A | $25,445,540 |
| Total Liabilities | N/A | N/A | $27,552,737 |
| Stockholders' Deficit | N/A | N/A | $(2,107,197) |
| Short-term Debt | N/A | N/A | $6,807,431 |
| Operating Cash Flow (9mo) | N/A | $(10,036,100) | N/A |
Material Changes vs. Prior Period
- Revenue Collapse: Revenues dropped significantly from $426,423 in Q3 2024 to $15,606 in Q3 2025. This is primarily due to the suspension of the Wugen License agreement on May 29, 2025, which halted the sale of clinical materials and reimbursement of R&D expenses.
- Legal Expense Recovery: Legal expenses (recoveries), net shifted from a $949,455 expense in Q3 2024 to a $6,006 expense in Q3 2025. For the nine-month period, the Company recorded a net recovery of $1.59 million, largely driven by a $2.0 million insurance reimbursement for prior legal defense costs related to the settled ImmunityBio arbitration.
- Debt Restructuring: The Company extinguished approximately $7.7 million of debt during the nine months ended September 30, 2025, through restructuring and conversion to equity. This included converting $6.6 million of Senior Secured Notes and $270,000 of unsecured promissory notes.
- Equity Financing: The Company raised approximately $7.0 million in gross proceeds through equity issuances, including a $5.0 million follow-on public offering in May 2025 and sales under a Standby Equity Purchase Agreement (SEPA).
- Investment Valuation: The Company elected to fair value its investment in Wugen Inc. shares in Q2 2025. In Q3 2025, this resulted in a $966,284 unrealized loss due to dilution from a Wugen capital raise, though the nine-month period showed a net gain of $782,404.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: Management has concluded there is substantial doubt about the Company's ability to continue as a going concern for at least 12 months from the issuance date. The Company has a stockholders' deficit of $2.1 million and cash of only $1.1 million. Continued operations depend on successful capital raises and business development transactions.
- Nasdaq Compliance: The Company is currently non-compliant with Nasdaq Listing Rule 5550(b)(1) (Equity Rule) requiring $2.5 million in stockholders' equity. The Nasdaq Hearings Panel granted an extension to regain compliance by December 31, 2025, with a final deadline of February 16, 2026.
- Legal Proceedings (Construction Liens): The Company faces litigation from its general contractor (BE&K) and subcontractors regarding unpaid invoices for its manufacturing facility. On October 24, 2025, the lender (Cogent Bank) demanded the Company cure these mechanics liens within 30 days to avoid default on the $6.2 million loan. Negotiations for a forbearance agreement are ongoing.
- Business Development: The Company is actively seeking partners for its T-cell engager and immune checkpoint inhibitor programs. Negotiations are ongoing to restructure the WY Biotech license agreement for molecule HCW11-006, which includes a potential $7.0 million upfront fee pending finalization.
- Government Shutdown: The U.S. federal government shutdown beginning October 1, 2025, has limited SEC operations, potentially restricting the Company's ability to access public markets for equity financing.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.1 million cash balance against the $10 million operating cash burn over the last nine months.
- Debt Default Risk: Confirm the status of negotiations with Cogent Bank regarding the mechanics lien cure demand and the potential acceleration of the $6.2 million loan.
- Nasdaq Status: Monitor the Company's progress toward meeting the $2.5 million stockholders' equity requirement by the December 31, 2025 deadline.
- Revenue Pipeline: Assess the likelihood of closing the WY Biotech license amendment and securing new partners for the suspended Wugen assets.
- Legal Liabilities: Review the payment plan discussions for the $12.1 million in accrued legal fees related to the settled ImmunityBio arbitration.